Optum is offering a whitepaper that provides insight into how real world data (RWD) can accelerate rare disease research. The paper identifies deidentified patient data, including electronic health records, as a robust source of RWD.
“Rare disease research and treatment development is uniquely challenging given the limited understanding of rare and genetic diseases. De-identified, real-world data (RWD) features claims and electronic health record (EHR) data. Read how this robust, longitudinal patient view makes RWD an invaluable tool for stakeholders across the health system.” Access the whitepaper here.
(Source: Optum, 2021)